Bio Farma

What Bio Farma does

PT Bio Farma (Persero) is an Indonesian state-owned vaccine manufacturer founded in 1893 and headquartered in Bandung, operating as the core entity of the Holding BUMN Farmasi under the Danantara sovereign wealth fund. The company produces vaccines and life sciences products with annual manufacturing capacity exceeding 3.5 billion doses, supplying national immunization programs in over 150 countries and serving multilateral procurement bodies including UNICEF, WHO, and Gavi. Bio Farma's product portfolio spans conventional vaccines (tetanus-diphtheria, DTaP/Tdap, oral polio vaccines) and includes the novel oral polio vaccine type 2 (nOPV2), which received the first WHO Emergency Use Listing in 2020. The company also provides consumer-facing services such as cervical cancer screening and operates an immunization services portal (updateimun.id), while pursuing next-generation platform development in mRNA and viral vector technologies.

Bio Farma's business model is anchored in long-term supply contracts with government health ministries and multilateral procurement agencies, complemented by technology transfer licensing (e.g., nOPV2 bulk technology licensed to Biological E. Limited). Distribution is handled primarily through UNICEF/WHO/Gavi channels and bilateral government-to-government agreements, with domestic Indonesian pharmaceutical and medical device distribution routed through affiliated entities Kimia Farma and Indofarma. The company generates licensing revenue from technology transfer arrangements and is expanding into adjacent verticals such as In Vitro Diagnostics via its partnership with PT Fapon. Pricing is not publicly disclosed and is negotiated bilaterally or through multilateral procurement mechanisms.

The company's competitive position rests on regulatory certifications (WHO prequalification, Emergency Use Listing, BPOM's WHO Listed Authority status), scale economics in GMP-certified manufacturing, and a dense institutional network through its chairmanship of the Developing Countries Vaccine Manufacturers' Network (DCVMN, 2023-2025). Bio Farma has executed two cross-border technology transfer agreements in the past year — to Ghana's National Vaccine Institute (June 2026, supporting local production by 2027) and to Biological E. Limited in India (February 2026). The broader Bio Farma Group includes subsidiaries Kimia Farma (pharmaceutical services), Indofarma (medicine and medical device distribution), and PT INUKI (nuclear medicine), with current leadership headed by President Director Shadiq Akasya.

Name

Bio Farma

Legal name

PT Bio Farma (Persero)

Website

https://biofarma.co.id

Company type

Private

Founded year

1893

Operating status

Operating

Headcount range

501–1,000 employees

Short description

PT Bio Farma (Persero) is Indonesia's state-owned vaccine manufacturer, producing more than 3.5 billion doses annually and supplying 150+ countries via UNICEF, WHO, and Gavi procurement. It developed the first WHO-listed nOPV2 vaccine and licenses technology to manufacturers globally.

Ownership category

akta.pro rank

Product category

Vaccine Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Food Manufacturing (311)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO) (HLAMAKAI)

akta.pro secondary industries

Veterinary Vaccines (HLAIAEAH), Vaccine Cold Chain, Storage & Distribution (HLAIAEAK)

Keywords

• Vaccine manufacturing
• Polio vaccines
• Biological products
• Immunization services
• Vaccine distribution

Headquarters

HQ city

Bandung

HQ country

Indonesia

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Vaccine and pharmaceutical product sales to governments and international agencies: Bio Farma generates revenue through the manufacture and sale of vaccines and life science products to government health ministries, multilateral procurement bodies (UNICEF, WHO, Gavi), and bilateral partners. Revenue is derived from long-term supply contracts, emergency procurement, and technology transfer arrangements.
2. Technology transfer and licensing: Bio Farma conducts technology transfer agreements with international partners, transferring vaccine manufacturing technology (e.g., nOPV2 bulk vaccine technology to Biological E. Limited) in exchange for licensing fees or reciprocal technology access.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Bio Farma manufactures vaccines and life sciences products including nOPV2 (novel oral polio vaccine type 2), tetanus-diphtheria, DTaP/Tdap, and other immunization products at GMP-certified facilities. The company also operates technology transfer programs to emerging vaccine manufacturers and provides direct immunization and cervical cancer screening services in Indonesia.

Product overview

PT Bio Farma (Bio Farma) is Indonesia's state-owned vaccine manufacturer and a leading Life Science company. The company operates as a single unified product portfolio focused on vaccine manufacturing and healthcare services. The core products include various vaccines (nOPV2, tetanus-diphtheria, DTaP/Tdap, oral polio vaccines) produced through their Life Sciences division, with an annual production capacity exceeding 3.5 billion doses supplying over 150 countries globally. The company also provides complementary healthcare services including cervical cancer screening and immunization services. Bio Farma's vaccine portfolio includes the nOPV2 vaccine which received WHO Emergency Use Listing in 2020, making it a key global health security contributor.

Differentiator

Problem solved

Functional benefit

Brands

• Bio Farma Group: The parent holding structure encompassing PT Bio Farma and its subsidiaries including Kimia Farma and Indofarma

Products and services

• Vaccines (Life Sciences) Broad portfolio of vaccines produced by Bio Farma including nOPV2 (novel oral polio vaccine type 2), tetanus-diphtheria, DTaP/Tdap, and other immunization products, supplied to over 150 countries with an annual production capacity of more than 3.5 billion doses.
• nOPV2 (Novel Oral Polio Vaccine Type 2) Novel oral polio vaccine type 2 developed by Bio Farma that received the first WHO Emergency Use Listing in 2020, designed to prevent outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2); technology subsequently transferred to Biological E. Limited in India.
• Cervical Cancer Screening Service Cervical cancer screening services offered by Bio Farma to support early detection and prevention of cervical cancer in Indonesian consumers.
• Immunization Services Immunization services provided by Bio Farma through the updateimun.id portal to support national vaccination programs and public health initiatives in Indonesia.

Quantifiable outcome

• WHO prequalified nOPV2 enabled rapid response to 136 of 143 reported cVDPV2 infections globally in 2025
• +1 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Ghana National Vaccine InstitutecoreStrategic or Co-development Partner · 5 June 2026Bio Farma signed a technology transfer agreement with Ghana's National Vaccine Institute to support local production of tetanus-diphtheria vaccine by 2027. President John Dramani Mahama allocated $50 million in seed funding for vaccine manufacturing, research, and development as part of Ghana's strategy to achieve vaccine self-sufficiency before Gavi support ends in 2030. Bio Farma will transfer production technology to local pharmaceutical companies Atlantic Life Sciences and DEK Vaccines Limited.
• Biological E. Limited (India)coreTechnology or Integration · 10 February 2026Bio Farma transferred bulk nOPV2 vaccine technology to Biological E. Limited in India. WHO prequalified the resulting nOPV2 vaccine manufactured by Biological E. on February 10, 2026. This expanded the pool of prequalified nOPV2 vaccines crucial for rapid response to circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks.
• PT FaponminorStrategic or Co-development Partner · 8 December 2025PT Fapon and PT Bio Farma established a strategic partnership to promote IVD (In Vitro Diagnostics) localization and innovation in Indonesia, combining Bio Farma's manufacturing expertise with Fapon's diagnostic technology capabilities.
• Developing Countries Vaccine Manufacturers' Network (DCVMN)coreStrategic or Co-development PartnerBio Farma has been an active member of DCVMN since its founding in 2000 and served as Chair of the network from 2023 to 2025. The company hosted the 26th DCVMN AGM in Bali in October 2025, bringing together 46 vaccine manufacturers from 17 countries. DCVMN focuses on vaccine innovation, supply resilience, and global health collaboration.
• WHO (World Health Organization)coreStrategic or Co-development PartnerBio Farma works with WHO on vaccine prequalification, Emergency Use Listing for nOPV2, and global health security initiatives. WHO prequalified Bio Farma's nOPV2 vaccine and the BPOM RI's WHO Listed Authority status further supports Bio Farma's global regulatory standing.
• Gavi, the Vaccine AlliancecoreStrategic or Co-development PartnerBio Farma collaborates with Gavi on vaccine supply for developing countries and supports Gavi's mission to increase equitable and sustainable vaccine access. The company is preparing for Gavi support transitions in countries like Ghana (ending in 2030).
• UNICEFcoreChannel Partner/ Reseller/ DistributorUNICEF is a key procurement partner for Bio Farma's vaccines, distributing Bio Farma's products (including nOPV2) to developing countries through its supply division as part of global immunization programs.
• CEPI (Coalition for Epidemic Preparedness Innovations)minorStrategic or Co-development PartnerBio Farma collaborates with CEPI as part of its efforts to enhance global health security and pandemic preparedness, working on vaccine development and technology advancement.
• BPOM RI (Badan Pengawas Obat dan Makanan)coreOthersBio Farma conducted a strategic audiensi (courtesy visit) with BPOM RI on April 27, 2026, focusing on strengthening collaboration in vaccine and biological product development, regulatory synergy for product registration and certification, and enhancing the competitiveness of Indonesia's life science industry globally. BPOM RI achieved WHO Listed Authority status, which supports Bio Farma's global competitiveness.
• Kimia Farma GroupcoreOthersBio Farma is part of the Holding BUMN Farmasi (State Pharmaceutical Holding Company) which includes Kimia Farma Tbk (KAEF), Indofarma Tbk (INAF), and PT INUKI. These subsidiaries handle pharmaceutical manufacturing, distribution, and specialized healthcare products within the Bio Farma Group ecosystem.
• Indofarma GroupcoreOthersBio Farma Group subsidiary handling trading and distribution of medicines and medical devices, operating as part of the integrated pharmaceutical distribution network under Holding BUMN Farmasi.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Biological E. Limited: Indian vaccine manufacturer that received Bio Farma's nOPV2 bulk technology transfer and secured WHO prequalification in February 2026. Comparable scale, DCVMN membership, and focus on WHO-prequalified vaccines for developing-country markets.
• Bharat Biotech: Indian vaccine manufacturer with WHO-prequalified products, DCVMN membership, and a comparable developing-country public-health focus. Known for novel vaccine development (Covaxin) and a similar scale of operations to Bio Farma.
• Sinovac Biotech: Chinese vaccine manufacturer and DCVMN member with WHO-prequalified products (including COVID-19 and influenza vaccines) supplying developing-country markets. Comparable in its focus on WHO PQ pathways and emerging-market distribution.
• SK Bioscience: South Korean vaccine manufacturer, DCVMN member, and WHO-prequalified supplier (including COVID-19 vaccines). Operates at a comparable scale to Bio Farma and serves similar global public-health procurement channels.
• Panacea Biotec: Indian vaccine manufacturer and DCVMN member with WHO-prequalified pediatric and polio vaccines. Operates at smaller scale than Bio Farma but shares similar product mix and focus on WHO PQ channels for emerging-market supply.
• Butantan Institute: Brazilian state-owned vaccine manufacturer with similar developing-country public-health mission, comparable production scale, and WHO-prequalified portfolio (including influenza and HPV). Both firms operate as national champions supplying public immunization programs and engaging in technology transfer.

Broad incumbents

• GSK Vaccines: Global vaccine incumbent within GSK with extensive WHO-prequalified portfolio (including polio IPV, pediatric combination vaccines). Multinational scale and broader geographic footprint, but overlaps with Bio Farma in pediatric immunization categories and emerging-market tenders.
• Sanofi Pasteur: Global vaccine incumbent (Sanofi division) with broad WHO-prequalified portfolio across pediatric, adult, and travel vaccines. Operates as a multinational with much larger scale, but competes with Bio Farma in some developing-country tenders and via technology transfer partnerships.
• Serum Institute of India: World's largest vaccine manufacturer by doses, supplying to over 170 countries with an extensive WHO-prequalified portfolio. Broader portfolio and larger scale than Bio Farma, but shares the DCVMN model of high-volume, cost-competitive vaccine supply for developing markets.
• Sinopharm: Chinese state-owned pharmaceutical and vaccine conglomerate with WHO-prequalified products (including COVID-19 vaccines). Significantly larger scale and broader portfolio, but similar state-owned structure and focus on emerging-market public-sector supply.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/results?search_query=Bio+Farma
• Xx.com/biofarmaid
• Facebookfacebook.com/infoimunisasi
• LinkedInlinkedin.com/company/bio-farma---indonesia

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bio Farma